A detailed history of Met Life Investment Management, LLC transactions in Insmed Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 89,622 shares of INSM stock, worth $6.33 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
89,622
Previous 89,570 0.06%
Holding current value
$6.33 Million
Previous $6 Million 9.02%
% of portfolio
0.04%
Previous 0.04%

Shares

51 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$62.0 - $79.01 $3,224 - $4,108
52 Added 0.06%
89,622 $6.54 Million
Q2 2024

Aug 13, 2024

BUY
$22.0 - $69.71 $407,990 - $1.29 Million
18,545 Added 26.11%
89,570 $6 Million
Q1 2024

May 14, 2024

BUY
$25.72 - $29.94 $1.83 Million - $2.13 Million
71,025 New
71,025 $1.93 Million
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $82,672 - $112,042
3,530 Added 5.12%
72,448 $2.25 Million
Q3 2023

May 09, 2024

SELL
$19.86 - $26.93 $38,151 - $51,732
-1,921 Reduced 2.71%
68,918 $1.74 Million
Q2 2023

Apr 29, 2024

BUY
$16.44 - $21.1 $1.13 Million - $1.45 Million
68,918 New
68,918 $1.45 Million
Q2 2023

Aug 10, 2023

SELL
$16.44 - $21.1 $31,581 - $40,533
-1,921 Reduced 2.71%
68,918 $1.45 Million
Q1 2023

May 09, 2024

BUY
$16.26 - $21.73 $1.15 Million - $1.54 Million
70,839 New
70,839 $1.21 Billion
Q4 2022

May 10, 2024

BUY
$16.98 - $23.15 $135,075 - $184,158
7,955 Added 12.65%
70,839 $1.42 Million
Q4 2022

Mar 22, 2023

BUY
$16.98 - $23.15 $135,075 - $184,158
7,955 Added 12.65%
70,839 $1.42 Million
Q4 2022

Feb 15, 2023

BUY
$16.98 - $23.15 $135,075 - $184,158
7,955 Added 12.65%
70,839 $1.42 Million
Q3 2022

Jun 14, 2023

SELL
$20.88 - $28.21 $166,100 - $224,410
-7,955 Reduced 11.23%
62,884 $1.35 Million
Q2 2022

Jun 20, 2023

SELL
$17.07 - $25.71 $135,791 - $204,523
-7,955 Reduced 11.23%
62,884 $1.24 Million
Q1 2022

May 10, 2024

BUY
$20.42 - $28.13 $1.28 Million - $1.77 Million
62,884 New
62,884 $1.48 Million
Q1 2022

Jun 20, 2023

SELL
$20.42 - $28.13 $162,441 - $223,774
-7,955 Reduced 11.23%
62,884 $1.48 Million
Q1 2022

Mar 22, 2023

BUY
$20.42 - $28.13 $466,209 - $642,236
22,831 Added 57.0%
62,884 $1.48 Million
Q1 2022

May 12, 2022

BUY
$20.42 - $28.13 $466,209 - $642,236
22,831 Added 57.0%
62,884 $1.48 Million
Q4 2021

Jun 21, 2023

SELL
$25.89 - $33.45 $797,049 - $1.03 Million
-30,786 Reduced 43.46%
40,053 $1.09 Million
Q3 2021

May 17, 2024

BUY
$22.46 - $29.47 $36,519 - $47,918
1,626 Added 4.23%
40,053 $1.1 Million
Q3 2021

Jun 21, 2023

SELL
$22.46 - $29.47 $691,453 - $907,263
-30,786 Reduced 43.46%
40,053 $1.1 Million
Q3 2021

Mar 22, 2023

BUY
$22.46 - $29.47 $36,519 - $47,918
1,626 Added 4.23%
40,053 $1.1 Million
Q3 2021

Nov 15, 2021

BUY
$22.46 - $29.47 $36,519 - $47,918
1,626 Added 4.23%
40,053 $1.1 Million
Q2 2021

Jun 21, 2023

SELL
$24.17 - $36.01 $783,398 - $1.17 Million
-32,412 Reduced 45.75%
38,427 $1.09 Million
Q1 2021

May 17, 2024

SELL
$32.28 - $44.3 $1.05 Million - $1.44 Million
-32,598 Reduced 45.9%
38,427 $1.31 Million
Q1 2021

Jun 26, 2023

SELL
$32.28 - $44.3 $1.05 Million - $1.44 Million
-32,412 Reduced 45.75%
38,427 $1.31 Billion
Q1 2021

Mar 22, 2023

SELL
$32.28 - $44.3 $109,622 - $150,442
-3,396 Reduced 8.12%
38,427 $1.31 Million
Q1 2021

May 14, 2021

SELL
$32.28 - $44.3 $109,622 - $150,442
-3,396 Reduced 8.12%
38,427 $1.31 Million
Q4 2020

May 24, 2024

SELL
$31.45 - $40.54 $93,500 - $120,525
-2,973 Reduced 6.64%
41,823 $1.39 Million
Q4 2020

Jun 22, 2023

SELL
$31.45 - $40.54 $912,553 - $1.18 Million
-29,016 Reduced 40.96%
41,823 $1.39 Million
Q4 2020

Mar 22, 2023

SELL
$31.45 - $40.54 $93,500 - $120,525
-2,973 Reduced 6.64%
41,823 $1.39 Million
Q4 2020

Feb 16, 2021

SELL
$31.45 - $40.54 $93,500 - $120,525
-2,973 Reduced 6.64%
41,823 $1.39 Million
Q3 2020

Jun 26, 2023

SELL
$26.0 - $34.5 $677,118 - $898,483
-26,043 Reduced 36.76%
44,796 $1.44 Million
Q2 2020

May 24, 2024

SELL
$14.11 - $29.42 $370,091 - $771,657
-26,229 Reduced 36.93%
44,796 $1.23 Billion
Q2 2020

Jun 26, 2023

SELL
$14.11 - $29.42 $367,466 - $766,185
-26,043 Reduced 36.76%
44,796 $1.23 Million
Q2 2020

Mar 22, 2023

BUY
$14.11 - $29.42 $73,541 - $153,337
5,212 Added 13.17%
44,796 $1.23 Million
Q2 2020

Aug 14, 2020

BUY
$14.11 - $29.42 $73,541 - $153,337
5,212 Added 13.17%
44,796 $1.23 Million
Q1 2020

Jul 12, 2023

SELL
$13.63 - $33.98 $426,005 - $1.06 Million
-31,255 Reduced 44.12%
39,584 $634,000
Q4 2019

Jul 12, 2023

SELL
$16.12 - $24.98 $503,830 - $780,749
-31,255 Reduced 44.12%
39,584 $945,000
Q3 2019

Jul 12, 2023

SELL
$15.49 - $25.78 $484,139 - $805,753
-31,255 Reduced 44.12%
39,584 $698,000
Q3 2019

Mar 22, 2023

BUY
$15.49 - $25.78 $98,376 - $163,728
6,351 Added 19.11%
39,584 $698,000
Q3 2019

Nov 14, 2019

BUY
$15.49 - $25.78 $98,376 - $163,728
6,351 Added 19.11%
39,584 $698,000
Q2 2019

Jul 12, 2023

SELL
$23.0 - $32.19 $777,929 - $1.09 Million
-33,823 Reduced 47.75%
37,016 $947,000
Q1 2019

Jul 13, 2023

SELL
$13.91 - $31.15 $523,099 - $1.17 Million
-37,606 Reduced 53.09%
33,233 $966,000
Q4 2018

Jul 13, 2023

SELL
$11.6 - $18.7 $436,229 - $703,232
-37,606 Reduced 53.09%
33,233 $436,000
Q4 2018

Mar 22, 2023

SELL
$11.6 - $18.7 $227,012 - $365,959
-19,570 Reduced 37.06%
33,233 $436,000
Q4 2018

Feb 14, 2019

SELL
$11.6 - $18.7 $227,012 - $365,959
-19,570 Reduced 37.06%
33,233 $436,000
Q3 2018

Jul 13, 2023

SELL
$18.95 - $28.08 $712,633 - $1.06 Million
-37,606 Reduced 53.09%
33,233 $671,000
Q3 2018

Mar 22, 2023

SELL
$18.95 - $28.08 $341,782 - $506,450
-18,036 Reduced 25.46%
52,803 $1.07 Million
Q3 2018

Nov 14, 2018

BUY
$18.95 - $28.08 $287,111 - $425,440
15,151 Added 40.24%
52,803 $1.07 Million
Q2 2018

Aug 15, 2018

BUY
$20.0 - $29.72 $83,200 - $123,635
4,160 Added 12.42%
37,652 $890,000
Q4 2017

Feb 15, 2018

BUY
$26.43 - $31.78 $885,193 - $1.06 Million
33,492
33,492 $1.04 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.56B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.